Abrupt Breathlessness: Pneumocystis jirovecii Pneumonia Associated with Inebilizumab in Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review
Abstract
Abstract Opportunistic infections pose significant challenges in patients undergoing immunosuppressive treatment for autoimmune disorders. Neuromyelitis optica spectrum disorder (NMOSD) is a rare disabling autoimmune condition requiring both acute attack management and long-term relapse prevention. B-cell depleting therapies, such as inebilizumab have demonstrated efficacy in reducing relapse rates and disability progression in NMOSD. Here, we present the first known NMOSD case who developed Pneumocystis jirovecii pneumonia following maintenance therapy with inebilizumab, showing a probable association (Naranjo score=6). We explored the underlying mechanisms linking B-cell depletion to Pneumocystis jirovecii, including antibody-dependent and immunomodulatory pathways. Furthermore, we provided an overview of Pneumocystis jirovecii pneumonia in autoimmune central nervous system disorders and summarized its clinical features, previous medication use, and prognostic factors. We advocate for risk-adapted prophylaxis to reduce morbidity and mortality associated with opportunistic infections in NMOSD.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.